Renovaro Inc. (NASDAQ:RENB - Get Free Report)'s share price traded up 6.5% on Wednesday . The company traded as high as $0.55 and last traded at $0.50. 450,750 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 535,915 shares. The stock had previously closed at $0.47.
Renovaro Stock Performance
The firm's 50 day moving average price is $0.55 and its 200-day moving average price is $0.93.
Renovaro (NASDAQ:RENB - Get Free Report) last issued its quarterly earnings data on Thursday, October 10th. The company reported ($0.45) EPS for the quarter.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Renovaro by 904.0% in the 1st quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company's stock valued at $10,379,000 after purchasing an additional 3,526,565 shares in the last quarter. State Street Corp lifted its stake in shares of Renovaro by 3.8% in the third quarter. State Street Corp now owns 1,323,832 shares of the company's stock worth $640,000 after buying an additional 48,114 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Renovaro during the 2nd quarter worth approximately $220,000. Barclays PLC grew its holdings in Renovaro by 315.7% in the 3rd quarter. Barclays PLC now owns 69,531 shares of the company's stock valued at $34,000 after buying an additional 52,804 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in Renovaro during the second quarter worth about $79,000. 71.41% of the stock is owned by hedge funds and other institutional investors.
About Renovaro
(
Get Free Report)
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
Further Reading
Before you consider Renovaro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Renovaro wasn't on the list.
While Renovaro currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
